July 2017 Tangen Biosciences receives a Notice of Intent to fund the SBIR/NIH phase I grant application for Rapid Detection of Multiple Sepsis Pathogens.
April 2017 Tangen Biosciences holds Pre-Submission meeting with FDA to discuss parameters for the clinical testing of the TangenDx direct-from-blood Fungal Panel in support of a planned 510(k) submission.
February 3, 2017 Tangen Biosciences has commenced the process of securing FDA clearance for its novel molecular diagnostic platform by submitting a Pre-Submission Package to the Center for Devices and Radiological Health of the Food and Drug Administration.
November 2016 Tangen successfully demonstrates the TangenDx Fungal Sepsis Panel at three clinical microbiology labs in the northeast region.
June 29th, 2016 Tangen Biosciences, Inc., has been awarded a Phase I SBIR grant from the National Institutes of Health to develop a rapid molecular assay for the detection of Multiple Drug Resistant Mycobacteria Tuberculosis (MDR-TB) in sputum. The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing Tangen TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity information. The MDR-TB assay panel will run on a single disposable disk in the TangenDx Instrument, a battery powered, portable, low cost, highly sensitive and simple to use molecular diagnostic platform.
January 2016 Tangen Biosciences is selected to present and Cavendish Global Impact Forum Press Release
Dec 2015 Tangen completes $2MM Seed Round equity financing http://www.hartfordbusiness.com/article/20151229/NEWS01/151229911/tangen-biosciences-raises-2m-in-equity-funding
Oct 2015 Tuberculosis article: http://ctinnovations.com/resource/134/tangen
June 2015 Tangen completes first TB clinical sample trial and submits results to the Foundation for Innovative New Diagnostics for review. System demonstrates sensitivity and specificity on par with the best state of the art molecular diagnostic systems.
May 2015 Tangen begins first blind clinical sample trial for infectious Tuberculosis detection
January 2015 Dr. Richard Carroll joins Tangen as VP of Business Development and Director of Clinical Affairs
December 2014 Tangen secures $500k investment from the Connecticut Bioscience Innovation Fund (CBIF): http://www.bioinnovationct.com/case-study-tangen-biosciences-branford-connecticut/
April 2014 Tangen relocates to combined lab & office space at 780 East Main Street in Branford Connecticut
January 2014 Tangen Biosciences secures Pre-Seed investment from Connecticut Innovations and Private angel investor